Multiple CAR-T cell therapy for B-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new type of CAR-T cell therapy that targets multiple markers on B-cell lymphoma cells. It is for patients whose lymphoma has certain surface markers and who are in reasonably good health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Patient must be older than 6 months.
- The lymphoma must have CD19 or certain other markers (CD22, CD70, PSMA, CD13, CD79b, or GD2) on the surface.
- The patient needs good general health (KPS score of 80 or higher) and a life expectancy of at least 1 month.
- Hemoglobin level must be at least 80 g/L.
- No active infections (like HIV, hepatitis B/C, or uncontrolled bacterial/fungal/viral infections).
- No steroids taken within the last week, and no prior CAR-T treatment that failed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a lab-made immune treatment (CAR-T cells) designed to attack cancer cells that carry CD19 or CD22. It may help people whose B-cell cancers have those markers, provided they meet safety and health requirements.
This trial tests a lab-made immune therapy called CAR-T that targets specific markers on B-cell leukemia/lymphoma cells. It may help people whose cancer has returned or did not respond after earlier CD19 CAR-T, by attacking the cancer cells using added targeting.
This trial tests a new type of immune cell therapy (4SCAR19U T cells) designed to attack B-cell cancers. It may be an option if your cancer has the CD19 protein and you haven't had a prior CAR-T treatment that failed.
This early-phase trial tests a customized immune cell therapy (CAR-T) that targets cancer cells with CD19 or CD70 markers on their surface. It may help your body fight the cancer by directing new immune cells to recognize and attack those cells.
This trial tests a new type of cell therapy that targets two markers (CD19 and CD20) on lymphoma cells. It is for patients whose lymphoma has come back or has not responded to standard treatments.
This trial studies a type of immune treatment (CAR-T cells) designed to calm overactive immune disease. It may help by aiming the therapy at immune cells involved in B-cell activity, but it has strict health and safety requirements.
Hear when a new B Cell Lymphoma (BCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.